FindTrial
Sign In

The mechanism of androgen receptor splicing variant 7 in antiandrogenic therapy of prostate cancer

The mechanism of androgen receptor splicing variant 7 in antiandrogenic therapy of prostate cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021162
Enrollment
Unknown
Registered
2019-01-31
Start date
2017-06-06
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Case series:No

Sponsors

Dalian Municipal Central Hospital Affiliated of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patient with prostatic hyperplasia; or patient with prostate cancer; 2. Aged 40 to 85 years old; 3. Patients with poor general condition and severe malnutrition; 4. Consent and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with endocrine, metabolic or other serious digestive diseases; 2. Patients with chronic hepatitis, cirrhosis, chronic nephritis and renal insufficiency; 3. After radiotherapy, radiotherapy, endocrine treatments; 4. Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
AR-V7;IGF-1;IGF-1R;FOXO3A;—

Countries

China

Contacts

Public ContactWang Yanlong

Dalian Medical University

13109827714@163.com+86 13109827714

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026